Biotech Values

[go seek]

from calendar

IDIX – NM283 releases at AASLD: 1) 24-week (interim) data from phase-2b in naïve patients; 2) 48-week (final) data in phase-2b refractory patients.

?? 2) 48-week (final) data in phase-2b refractory patients.
perhaps, perhaps not...as you know, no abstract posted to date for AASLD on this study.

thanks for your work on this board...
Best wishes...